- 13
- 11 351
ArvinasInc
Registrace 11. 09. 2020
Leading the way in targeted protein degradation therapeutics, Arvinas is a clinical-stage biopharmaceutical company focused on developing new therapeutics for cancers and other difficult-to-treat diseases. Arvinas’ proprietary PROTAC® (PROteolysis-TArgeting Chimeras) protein degraders work by harnessing the body’s own natural protein disposal system to degrade and remove disease-causing cellular proteins via proteolysis. The company is translating protein degradation into novel drugs for the treatment of cancer, neurological disorders, and other diseases, and offers the potential to target “undruggable” as well as “druggable” elements of the proteome. This greatly expands the ability to create drugs for many new, previously unapproachable targets. For more information, visit www.arvinas.com.
Arvinas PROTAC® protein degraders - General
Arvinas has developed PROTAC® protein degraders, or PROteolysis -Targeting Chimeras which are novel molecules that direct the ubiquitin-proteasome system to specifically destroy disease-causing proteins, such as those causing cancer or neurodegenerative diseases.
zhlédnutí: 1 027
Video
Arvinas PROTAC® protein degraders - HCP
zhlédnutí 4,3KPřed rokem
Arvinas has developed PROTAC® protein degraders, or PROteolysis -Targeting Chimeras which are novel molecules that direct the ubiquitin-proteasome system to specifically destroy disease-causing proteins, such as those causing cancer or neurodegenerative diseases.
How it Works: Proteolysis Targeting Chimeras (PROTAC® degraders)
zhlédnutí 2,4KPřed 3 lety
Arvinas is engineering an expansive pipeline of proteolysis targeting chimeras, or PROTAC® protein degraders, designed to harness the body’s own natural protein disposal system (the ubiquitin proteasome system) to selectively and efficiently degrade and remove disease-causing proteins.
Working At Arvinas
zhlédnutí 2,4KPřed 3 lety
At Arvinas, there is an undercurrent of passion and curiosity driven by amazing science. Targeted protein degradation is an entirely new approach to drug development - one that could dramatically change the lives of patients who have few or no therapeutic options. But while we take our work very seriously, we also ensure we’re having fun while doing it. We embrace the freedom to pursue innovati...